A Real-world Study of Inetetamab for First-line Treatment of MBC
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-75
SponsorHunan Cancer Hospital
About this trial
This is a prospective, multicenter, real-world study aimed at evaluating the efficacy and safety of inetetamab+chemotherapy or inetetamab+pyrotinib+chemotherapy or inetetamab+pertuzumab+chemotherapy in the treatment of HER2 positive inoperable locally advanced or recurrent metastatic breast cancer. The research results will provide new targeted treatment strategies for HER2 positive breast cancer patients.
Eligibility criteria
Qualifiers
Patients aged ≥18 years and ≤75 years;Patients aged ≥18 years and ≤75 years;
At least one measurable lesion was present according to RECIST1.1 criteria;
The ECOG score is 0 to 1;
No systematic antitumor therapy (except first-line endocrine therapy) has been received at the locally advanced stage (clinically inoperable) or at the stage of recurrence and metastasis;
Disqualifiers
Known allergic history of drug components of the program;
Patients judged unsuitable for systematic chemotherapy by researchers;
Use of endocrine therapy drugs within 14 days before baseline;
Patients with only bone or skin as target lesions;
Trial design
Treatments tested in this trial
- Inetetamab
Treatment groups
150 Participants
are divided into 1 treatment groupLocations
Sponsors and collaborators
Hunan Cancer Hospital
Lead sponsor
Hunan Medical University General Hospital
Collaborator
Source ClinicalTrials.gov